Clinical trials: Desmoid Tumor
Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP)
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)
RIPAF (Rete Italiana Poliposi Adenomatosa Familiare) is a national, multicenter observational registry designed to establish a coordinated Italian network for the management of Familial Adenomatous Polyposis (FAP) and related…
- Conditions
- Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP), MUTYH-Associated Polyposis (MAP), Non-APC/MUTYH Associated Polyposis (NAMP)
- Trial name
- RIPAF (NCT07461246)
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Adrenal Gland Pheochromocytoma, Carcinoma In Situ
Project: Every Child for Younger Patients With Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and…
- Conditions
- Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma
- Trial name
- NCT02402244
- Testing
- Cytology Specimen Collection Procedure, Medical Chart Review
- Where
- 279 sites in United States, Australia and 4 more
- Volunteers
- 75,000 people
- Sponsor
- Children's Oncology Group
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Advanced Desmoid Tumor, Advanced Chondrosarcoma
Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived growth factor (PDGF) both in its isoform…
- Trial name
- Basket 1 (NCT00928525)
- Testing
- Imatinib Mesylate
- Where
- 7 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Italian Sarcoma Group
Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
- Trial name
- TUPELO (NCT05552755)
- Testing
- REC-4881
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Rhabdomyosarcoma, Neuroblastoma
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
The purpose of this study is to determine whether Doxil (liposomal doxorubicin) given prior to MR-HIFU Hyperthermia is safe for the treatment of pediatric and young adult patients with recurrent and refractory solid tumors.
- Conditions
- Rhabdomyosarcoma, Neuroblastoma, Sarcoma, Sarcoma, Ewing
- Trial name
- NCT02557854
- Testing
- Doxorubicin HCl liposomal injection, Philips Sonalleve MR-HIFU Hyperthermia
- Where
- United States
- Sponsor
- Theodore Laetsch
Hormone Receptor-Positive Breast, Gynecologic
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Background: Some types of cancer cells that have hormone receptors on their surfaces need the hormone estrogen to grow. The drug tamoxifen blocks estrogen from binding to the tumor cells, which helps to slow or stop the growth of…
- Conditions
- Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
- Trial name
- NCT01273168
- Testing
- Z-Endoxifen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Desmoid Tumor
Radiation Therapy in Treating Patients With Aggressive Fibromatoses
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients who have aggressive fibromatoses.
- Trial name
- NCT00030680
- Testing
- radiation therapy
- Where
- 21 sites in Belgium, France and 5 more
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Desmoid Tumors, Fibromatosis
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
The purpose of this study is to examine the response rate of desmoid tumors to hydroxyurea. The investigators hypothesize that hydroxyurea will be a safe, non-toxic alternative to aggressive surgery or chemotherapy for this…
- Trial name
- NCT00978146
- Testing
- Hydroxyurea
- Sponsor
- Children's Hospital of Philadelphia
Desmoid Tumors
Cryoablation for Advanced and Refractory Desmoid Tumors
Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors with no potential for metastasis. The incidence is approximately 2 to 4 per million per year in the general population.
- Trial name
- CARDT (NCT06113094)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Brachytherapy, Desmoid Tumor
CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 (I-125) seed implantation (RISI) for recurrent desmoid tumor.
- Conditions
- Brachytherapy, Desmoid Tumor, Radioactive Iodine-125 Seed Implantation
- Trial name
- NCT06195085
- Testing
- CT-guided radioactive iodine-125 seed implantation
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Peking University Third Hospital
Sarcoma
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
- Trial name
- TNT (NCT03886311)
- Testing
- Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Dermoid
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
- Trial name
- MP-VAC-206 (NCT06219733)
- Testing
- Vactosertib, Imatinib
- Where
- South Korea
- Sponsor
- MedPacto, Inc.
Aggressive Fibromatosis, Desmoid Tumor
Study to Evaluate Imatinib in Desmoid Tumors
The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily…
- Trial name
- NCT01137916
- Testing
- Imatinib
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- Heidelberg University
Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about…
- Conditions
- Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma
- Trial name
- NCT01567046
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Children's Oncology Group
Desmoid Tumor, Aggressive Fibromatosis
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive…
- Trial name
- DeFi (NCT03785964)
- Testing
- Nirogacestat oral tablet
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 142 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Gardner Syndrome, Colorectal Carcinoma
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
The purpose of this study is to assess the long-term outcome in a cohort of Gardner-Syndrome patients receiving prophylaxis and treatment for intestinal and non-intestinal tumors.
- Conditions
- Gardner Syndrome, Colorectal Carcinoma, Desmoid Tumor
- Trial name
- NCT01286662
- Volunteers
- 105 people
- Sponsor
- Triemli Hospital
Desmoid Tumor, NOTCH Gene Mutation Positive Tumors
Individual Patient Compassionate Use of Nirogacestat
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
- Trial name
- NCT05041036
- Testing
- Nirogacestat (Gamma Secretase Inhibitor)
- Where
- 2 sites in United States, Germany
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Desmoid Tumor, Desmoid-type Fibromatosis
Quality of Life of Patients With Desmoid-type Fibromatosis
Rationale: Desmoid-type fibromatosis (DTF) is a rare, histologically benign, soft tissue tumour. Although incapable of metastasizing, the clinical course is unpredictable and can be aggressive because of local invasive growth.
- Trial name
- QUALIFIED (NCT04289077)
- Testing
- Questionnaires
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Erasmus Medical Center